Itamar Medical (ITMR) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Itamar Medical (ITMR) today and set a price target of $30.00. The company’s shares closed last Wednesday at $24.34.
According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 28.8% and a 70.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Oramed Pharmaceuticals.
Currently, the analyst consensus on Itamar Medical is a Moderate Buy with an average price target of $30.00.
See today’s analyst top recommended stocks >>
Itamar Medical’s market cap is currently $345.3M and has a P/E ratio of -18.50. The company has a Price to Book ratio of 6.99.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.